Skyrizi Subcutaneous (pens or syringes) — Cigna

Initial criteria

• Patient age ≥ 18 years
• Medication prescribed by or in consultation with a rheumatologist or a dermatologist

Reauthorization criteria

• Patient established on therapy for at least 6 months
• Patient meets ≥ 1 of the following: (a) When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (prior to initiating Skyrizi); OR (b) Compared with baseline, patient experienced an improvement in at least one symptom such as less joint pain, morning stiffness, or fatigue; improved function or activities of daily living; or decreased soft tissue swelling in joints or tendon sheaths

Approval duration

initial 6 months; renewal 1 year